Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. lowered its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 8.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 322,734 shares of the company's stock after selling 31,595 shares during the quarter. EFG Asset Management North America Corp.'s holdings in Roivant Sciences were worth $3,820,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its holdings in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after buying an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Roivant Sciences by 6.1% during the fourth quarter. Victory Capital Management Inc. now owns 27,494 shares of the company's stock worth $325,000 after purchasing an additional 1,588 shares during the last quarter. United Services Automobile Association lifted its stake in Roivant Sciences by 6.1% during the fourth quarter. United Services Automobile Association now owns 27,494 shares of the company's stock worth $325,000 after purchasing an additional 1,588 shares during the last quarter. Finally, M&T Bank Corp increased its stake in Roivant Sciences by 16.3% in the fourth quarter. M&T Bank Corp now owns 13,194 shares of the company's stock valued at $156,000 after purchasing an additional 1,851 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Remove Ads

Roivant Sciences Stock Performance

Roivant Sciences stock traded down $0.10 during trading hours on Friday, reaching $10.38. 3,942,656 shares of the stock were exchanged, compared to its average volume of 5,393,763. Roivant Sciences Ltd. has a 52-week low of $9.96 and a 52-week high of $13.06. The stock has a market cap of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26. The firm's 50 day moving average is $10.74 and its 200 day moving average is $11.41.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Equities research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

ROIV has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $17.10.

Insider Activity at Roivant Sciences

In other news, COO Eric Venker sold 434,478 shares of Roivant Sciences stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This trade represents a 27.82 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the firm's stock in a transaction dated Monday, January 13th. The shares were purchased at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 1,573,245 shares of company stock worth $17,079,242 over the last three months. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.